REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Play Australian rules football at any level; Enter the club premises or clubrooms on game day; Train under the direction of a club-devised program; or Return to their clubs' training sessions until two months before their bans expired. Because of these limitations, the bans also covered most forms of coaching. As such, two former players (Mark McVeigh and Henry Slattery) who were employed as non-playing coaches were suspended from their jobs, and players serving as playing coaches in country leagues were suspended from performing either function. The bans extended to any sport administered by a signatory to the WADA code, precluding active involvement in almost any organised sport during 2016. Players were not completely banned from involvement with the AFL, and were permitted to:
Alcohol: "Euphoria, the feeling of well-being, has been reported during the early (10–15 min) phase of alcohol consumption" (e.g., beer, wine or spirits) Cannabis: Tetrahydrocannabinol, the main psychoactive ingredient in this plant, can have sedative and euphoric properties. Catnip: Catnip contains a sedative known as nepetalactone that activates opioid receptors. In cats it elicits sniffing, licking, chewing, head shaking, rolling, and rubbing which are indicators of pleasure. In humans, however, catnip does not act as a euphoriant. Stimulants: "Psychomotor stimulants produce locomotor activity (the subject becomes hyperactive), euphoria, (often expressed by excessive talking and garrulous behaviour), and anorexia. The amphetamines are the best known drugs in this category..." MDMA: The "euphoriant drugs such as MDMA ('ecstasy') and MDEA ('eve')" are popular among young adults. MDMA "users experience short-term feelings of euphoria, rushes of energy and increased tactility" as well as interpersonal connectedness. Opium: This "drug derived from the unripe seed-pods of the opium poppy…produces drowsiness and euphoria and reduces pain. Morphine and codeine are opium derivatives." Opioids have led to many deaths in the United States, particularly by causing respiratory depression.
H–D exchange has been used to characterize protein structures and protein–protein interactions. The exchange reaction needs to be carried out with the isolated proteins and with the complex. The exchanging regions are then compared. If a region is buried by the binding, the amides in this region may be protected in the complex and exchange slowly. However, one must bear in mind that H–D exchange cannot be used to locate binding interfaces for all protein-protein interactions. Some protein-protein interactions are driven by electrostatic forces of side chains and are unlikely to change the exchange rate of backbone amide hydrogens, particularly if the amide hydrogens are located in stable structural elements such as alpha helices. Lastly, H–D exchange can be used to monitor conformational changes in proteins as they relate to protein function. If conformation is altered as result of post-translational modification, enzyme activation, drug binding or other functional events, there will likely be a change to H/D exchange that can be detected.
== Further reading == "New Guidelines Seek to Provide Clarity on Food Expiration Dates". All Things Considered. U.S.: NPR. 17 February 2017. Includes a list of the many terms used in the United States food industry. Anonymous, "Cold Chain Management", 2003, 2006 Anonymous, Protecting Perishable Foods During Transport by Truck Archived 2014-05-16 at the Wayback Machine, USDA Handbook 669, 1995 Kilcast, D., Subramamiam, P., Food and Beverage Stability and Shelf Life, Woodhead Publishing, 2011, ISBN 978-1-84569-701-3 Labuza, T. P., Szybist, L., Open dating of Foods, Food and Nutrition Press, 2001; other edition: Wiley-Blackwell, 2004, ISBN 0-917678-53-2 Man, C. M., Jones. A. A., Shelf-Life Evaluation of Foods, ISBN 0-8342-1782-1 Robertson, G.L., Food Packaging and Shelf Life: A Practical Guide, CRC Press, 2010, ISBN 978-1-4200-7844-2 Steele, R., Understanding and Measuring the Shelf-Life of Food, Woodhead Publishing, 2004, ISBN 1-85573-732-9 Weenen, H., Cadwallader, K., Freshness and Shelf Life of Foods, ACS, 2002, ISBN 0-8412-3801-4
=== Space age swimsuit === Langley Research Center's wind tunnel testing facilities and fluid flow analysis software supported Speedo's design of a space age-enriched swimsuit. The resulting LZR Racer reduced skin friction drag 24% more than the previous Speedo swimsuit. In March 2008, athletes wearing the LZR Racer broke 13 swimming world records.
Sources: en.wikipedia.org
== Further reading == Allen, Jeannie (6 September 2001). Ultraviolet Radiation: How it Affects Life on Earth. Earth Observatory. NASA, USA. Hockberger, Philip E. (2002). "A History of Ultraviolet Photobiology for Humans, Animals and Microorganisms". Photochemistry and Photobiology. 76 (6): 561–569. doi:10.1562/0031-8655(2002)0760561AHOUPF2.0.CO2. PMID 12511035. S2CID 222100404. Hu, S; Ma, F; Collado-Mesa, F; Kirsner, R. S. (July 2004). "UV radiation, latitude, and melanoma in US Hispanics and blacks". Arch. Dermatol. 140 (7): 819–824. doi:10.1001/archderm.140.7.819. PMID 15262692. Strauss, CEM; Funk, DJ (1991). "Broadly tunable difference-frequency generation of VUV using two-photon resonances in H2 and Kr". Optics Letters. 16 (15): 1192–4. Bibcode:1991OptL...16.1192S. doi:10.1364/ol.16.001192. PMID 19776917.
== Etymology == In Old Japanese, me stood for edible seaweeds in general as opposed to mo standing for algae. In kanji, such as 海藻, 軍布 and 和布 were applied to transcribe the word. Among seaweeds, wakame was likely most often eaten, therefore me especially meant wakame. It expanded later to other seaweeds like kajime, hirome (kombu), arame, etc. Wakame is derived from waka + me (若布, lit. 'young seaweed'). If this waka is a eulogistic prefix, the same as the tama of tamagushi, wakame likely stood for seaweeds widely in ancient times. In the Man'yōshū, in addition to 和可米 and 稚海藻 (both are read as wakame), nigime (和海藻, soft wakame) can be seen. Besides, tamamo (玉藻, lit. 'beautiful algae'), which often appeared in the Man'yōshū, may be wakame depending on poems.
As of October 2024, Novo was the second most valuable drug company in the world by market capitalization, second only to its competitor Eli Lilly and Company. By July 2025, Novo had fallen to become the fifth most valuable drug company amid rising competition from generic weight loss substitutes. The company named Maziar Mike Doustdar as the new CEO, effective August 7, 2025. In March 2025, the company announced new plans for a direct-to-consumer offering of its Wegovy weight loss drug. The company established a new pharmacy, called NovoCare, which would charge customers $499 per month for access to the drug, less than half the cost of the drug through other pharmaceutical distribution networks. In September 2025, Novo announced that it would reduce its global workforce by 9,000 people, approximately 9% of its total workforce. In October 2025, Novo acquired Akero Therapeutics for $5.2 billion. Akero Therapeutics is a clinical stage company focusing on the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
== S == safe sex – safer sex – salmonella – salvage therapy – SAMHSA – sarcoma – seborrheic dermatitis – secondary prophylaxis – sepsis – seroconversion – serologic test – seroprevalence – serosorting – serostatus – serum – serum glutamic oxaloacetic transaminase (SGOT) – serum glutamic pyruvate transaminase (SGPT) – sexually transmitted disease (STD) – shingles – SHIV – side effects – simian immunodeficiency virus (SIV) – sinusitis – social integration SIT – SIV – Special Projects of National Significance (SPNS) – spinal tap – spleen – splenomegaly – sputum analysis – standard of care – staphylococcus – STD – stem cells (FDCs) – steroid – Stevens–Johnson syndrome – STI – stomatitis – strain – stratification – structured intermittent therapy (SIT) – structured treatment interruption (STI) – study endpoint – subarachnoid space – subclinical infection – subcutaneous (SQ) – Substance Abuse and Mental Health Services Administration (SAMHSA) – subunit HIV vaccine – sulfa drug – sulfonamides – superantigen – suppressor T cell – surrogate marker – surveillance – susceptible – symptoms – syncytium – syndrome – synergy – synergistic – synthesis – syphilis – systemic
=== Environmental and health concerns === Fluoroalkanes are generally inert and non-toxic. Fluoroalkanes are not ozone depleting, as they contain no chlorine or bromine atoms, and they are sometimes used as replacements for ozone-depleting chemicals. The term fluorocarbon is used rather loosely to include any chemical containing fluorine and carbon, including chlorofluorocarbons, which are ozone depleting. Perfluoroalkanes used in medical procedures are rapidly excreted from the body, primarily via expiration with the rate of excretion as a function of the vapour pressure; the half-life for octafluoropropane is less than 2 minutes, compared to about a week for perfluorodecalin.
Sources: en.wikipedia.org
== Applications == In 1997, Roberts and Szostak showed that fusions between a synthetic mRNA and its encoded myc epitope could be enriched from a pool of random sequence mRNA-peptide fusions by immunoprecipitation. Nine years later, Fukuda and colleagues chose mRNA display method for in vitro evolution of single-chain Fv (scFv) antibody fragments. They selected six different scFv mutants with five consensus mutations. However, kinetic analysis of these mutants showed that their antigen-specificity remained similar to that of the wild type. However, they have demonstrated that two of the five consensus mutations were within the complementarity determining regions (CDRs). And they concluded that mRNA display has the potential for rapid artificial evolution of high-affinity diagnostic and therapeutic antibodies by optimizing their CDRs. Roberts and coworkers have demonstrated that unnatural peptide oligomers consisting of an N-substituted amino acid can be synthesized as mRNA-peptide fusions. N-substituted amino acid-containing peptides have been associated with good proteolytic stability and improved pharmacokinetic properties. This work indicates that mRNA display technology has the potential for selecting drug-like peptides for therapeutic usage resistant to proteolysis.
Mammal classification has been through several revisions since Carl Linnaeus initially defined the class, and at present, no classification system is universally accepted. McKenna & Bell (1997) and Wilson & Reeder (2005) provide useful recent compendiums. Simpson (1945) provides systematics of mammal origins and relationships that had been taught universally until the end of the 20th century. However, since 1945, a large amount of new and more detailed information has gradually been found: The paleontological record has been recalibrated, and the intervening years have seen much debate and progress concerning the theoretical underpinnings of systematization itself, partly through the new concept of cladistics. Though fieldwork and lab work progressively outdated Simpson's classification, it remains the closest thing to an official classification of mammals, despite its known issues. Most mammals, including the six most species-rich orders, belong to the placental group. The three largest orders in numbers of species are Rodentia: mice, rats, porcupines, beavers, capybaras, and other gnawing mammals; Chiroptera: bats; and Eulipotyphla: shrews, moles, and solenodons. The next three biggest orders, depending on the biological classification scheme used, are the primates: apes, monkeys, and lemurs; Cetartiodactyla: whales and even-toed ungulates; and Carnivora which includes cats, dogs, weasels, bears, seals, and allies. According to Mammal Species of the World, 5,416 species were identified in 2006. These were grouped into 1,229 genera, 153 families and 29 orders.
=== Animal rights === Barker was a vegetarian. In 1982, Barker began ending The Price Is Right episodes with the phrase: "This is Bob Barker reminding you to help control the pet population – have your pets spayed or neutered." Though Barker had already been dabbling in animal rights before meeting Burnet, his efforts became more aggressive during his relationship with her. In 1987, Barker requested the removal of fur prizes for the Miss USA pageant and stepped down as host when the producers refused. In 1989, Barker and United Activists for Animal Rights publicly accused several media projects and the American Humane Association of animal mistreatment and condoning animal mistreatment, a tactic which resulted in a $10 million suit against him and the UAAR for libel, slander, and invasion of privacy. The suit was finally settled by the insurer in 1994. Barker founded DJ&T Foundation in 1994, named after his late wife and mother, which has contributed millions of dollars to animal-neutering programs and funded animal rescue and park facilities all over the United States. In 2004, Barker donated $1 million (equivalent to $1.7 million in 2025) to Columbia Law School to support the study of animal rights. In 2009, Barker wrote a letter about three businesses in Cherokee, North Carolina, asking them to close their bear exhibits. He threatened to not attend the 2009 Game Show Awards, where Barker was to receive a lifetime achievement award, because Betty White would be attending.
=== The Middle === Shaffer is most known for his role as Brick Heck in The Middle, which he played throughout the series' entire nine-season run, from 2009 to 2018. In a Wired magazine interview published in January 2013, Shaffer said his role as Brick was similar to his own life, as he is also a "big reader" and "nerd[s] out over the weirdest stuff". In May 2011, a TV Guide article had reported the closeness as well. Brick's characterization, including his idiosyncratic palilalian repetition of words and phrases at the end of sentences, is based on Justin Heisler, the son of The Middle co-creator Eileen Heisler.
124Xe (n,γ) → 125mXe (57 s) → 125I 124Xe (n,γ) → 125gXe (16.9 h) → 125I The irradiation target is the primordial nuclide 124Xe, which is the target isotope for making 125I by neutron capture. It is loaded into irradiation capsules of the zirconium alloy zircaloy-2 (a corrosion resisting alloy transparent to neutrons) to a pressure of about 100 bar (~ 100 atm). Upon irradiation with slow neutrons in a nuclear reactor, several radioisotopes of xenon are produced. However, only the decay of 125Xe leads to a radioiodine: 125I. The other xenon radioisotopes decay either to stable xenon, or to various caesium isotopes, some of them radioactive (i.e., caesium-135 and caesium-137). Long irradiation times are disadvantageous. Iodine-125 itself has a neutron capture cross section of 900 barns, and consequently during a long irradiation, part of the 125I formed will be converted to 126I, a beta-emitter and positron-emitter with a half-life of 12.93 days, which is not medically useful. In practice, the most useful irradiation time in the reactor amounts to a few days. Thereafter, the irradiated gas is allowed to decay for three or four days to eliminate short-lived unwanted radioisotopes, and to allow the newly produced xenon-125 to decay to iodine-125. To isolate the radioiodine, the irradiated capsule is first cooled at low temperature (to condense the free iodine gas onto the capsule inner wall) and the remaining Xe gas is vented in a controlled way and recovered for further use.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.